ReviewEndocrinology2022
Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology.
Review in Endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Racial, ethnic, sex, and age representation in clinical trials of radiopharmaceutical tumor therapy: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Pooled it
- Predictors of treatment refusal in patients with colorectal cancer: A systematic review.Seminars in oncology · 2022Pooled it
- Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects.EBioMedicine · 2025Trial
- Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Trial
- Trial
- Differential impact of cancer- and chemotherapy-induced cachexia: a comparative analysis in a preclinical model of colorectal cancer by biological sex.American journal of physiology. Endocrinology and metabolism · 2026Article
- Gender Oncology: Rethinking Cancer Through a Sex- and Gender-Based Lens.Journal of clinical medicine · 2026Article
- Prognostic value of CT-defined sarcopenic obesity in hepatocellular carcinoma patients undergoing transarterial chemoembolization.BMC gastroenterology · 2026Article
- Artificial intelligence in cancer diagnosis and therapy using sex and gender as precision biomarkers.Discover oncology · 2026Review
- Review
- Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study.Annals of hematology · 2026Article
- Impact of CYP and ABCB1 Polymorphisms on Bortezomib-Induced Adverse Events in Multiple Myeloma.Biomedicines · 2026Article
- Lack of De-Intensification Models for Female Head and Neck Cancer Patients With Favorable Prognosis.Cancer medicine · 2026Article
- Tailoring of metal organic framework with electrospun polyacrylonitrile for on-chip electromembrane extraction and determination of anticancer drugs in biological samples.Mikrochimica acta · 2026Article
- Increased reporting of interstitial pneumonitis with combined EGFR-TKI and PD-1/PD-L1 inhibitor therapy in NSCLC: a pharmacovigilance analysis of 67,818 reports.Frontiers in immunology · 2026Observational
- Sex-Related Safety Signals of Sotorasib in Non-Small Cell Lung Cancer: A Real-World, Pharmacovigilance Study from the EudraVigilance Database.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Treatment of Lung Cancer in Women.Surgical oncology clinics of North America · 2025Review
- Sex and gender differences in cancer pathogenesis and pharmacology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Sex-Associated Differences in Outcomes in Acute Myeloid Leukemia Patients Following Intense Induction Treatment: A Real-World Single Center Analysis.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The practice of oncology has dramatically changed in the last decade with the introduction of molecular tumor profiling into routine tumor diagnostics and the extraordinary progress in immunotherapies. However, there remains an unmet need to explore personalized dosing strategies that take into account the patient's sex and gender to optimize the balance between efficacy and toxicity for each individual patient. In this mini-review, we summarize the evidence on sex and gender differences in toxicity of anticancer therapies and present data on dose reduction and dose discontinuation rates for selected chemotherapies and targeted therapies. Finally, we propose the investigation of body composition (specifically fat-free muscle mass) as a viable approach for personalized treatment dosage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.